154
Participants
Start Date
May 9, 2022
Primary Completion Date
March 22, 2023
Study Completion Date
December 21, 2023
Olezarsen
Olezarsen will be administered by SC injection.
Placebo
Olezarsen-matching placebo will be administered once every 4 weeks by SC injection for up to 49 weeks.
Green and Seidner Family Practice Associates, Lansdale
Manassas Clinical Research Center, Manassas
York Clinical Research LLC, Norfolk
Main Street Physicians Care Waterway, Little River
IACT Health, Columbus
Research Physicians Network Alliance, Winter Park
De La Cruz Research Center, Miami
Excel Medical Clinical Trials, LLC, Boca Raton
Suncoast Clinical Research, Inc., New Port Richey
Tennessee Center for Clinical Trials, Tullahoma
Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville
Aa Mrc, Llc, Flint
West Broadway Clinic, Council Bluffs
Health Concepts, Rapid City
Clinical Investigation Specialist, Gurnee
Evanston Premier Healthcare Research, Evanston
Southern Endocrinology Associates, Mesquite
Clinical Research of South Nevada, Las Vegas
Palm Research Center, Inc., Las Vegas
Catalina Research Institute, LLC, Montclair
Clinical Trials Research, Lincoln
Bluewater Clinical Research Group Inc, Sarnia
Ecogene-21, Chicoutimi
Clinique des Maladies Lipidiques de Quebec Inc., Québec
Lead Sponsor
Ionis Pharmaceuticals, Inc.
INDUSTRY